China’s New Stem Cell Guidelines To Shake Up Industry?
This article was originally published in PharmAsia News
China is releasing additional regulations governing clinical trials with stem cell therapies following its first new administrative measures this year, in order to better regulate the market. The changes are expected to result in a reshuffle of the industry and the flushing out of up to 80% of companies currently involved in the field, with the focus of the supply chain set to shift to the middle ground.
Register for our free email digests: